評論
打印
Nordisk's top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent
據(jù)研究報告表明，最暢銷降糖藥Victoza可降低心臟病中風，以及心血管死亡風險，減少比例達13%，
in a closely watched study that may help boost sales of the injectable medicine.
該項研究有望增加注射類藥物銷量。
Victoza is only the second diabetes drug to show such heart benefits.
Victoza也是全球第二種有益心臟的降糖藥物。
John Buse, professor of medicine at the UNC School of Medicine, who worked on the study said,
來自北卡醫(yī)學院的研究人員約翰·布斯認為，
"To me, the impressive thing about this trial is the consistency across clinical endpoints and its robustness."
我認為最讓人感到意外的是，該藥物在臨床試驗終點以及魯棒性的一致性。
Because about half of deaths in people with diabetes are caused by heart disease,
在所有糖尿病患者中，大約一半都是因心臟疾病死亡，
reducing heart risk is considered essential to their care.
降低心臟病風險是治療的重中之重。
譯文屬可可英語創(chuàng)，未經(jīng)允許，不得轉(zhuǎn)載。
